Figure 6
Effects of rosiglitazone on BPA-induced APP, BACE-1 and Aβ1–42 expressions. (A) Effect of rosiglitazone on the expression of APP protein mediated by BPA in SY5Y cells. (C) Effect of rosiglitazone on the expression of APP protein mediated by BPA in PC-12 cells. (E) Effect of rosiglitazone on the expression of BACE-1 protein mediated by BPA in PC-12 cells. (B,D,F,H) GAPDH levels were assessed in parallel and served as controls. (I) ELISA analysis of the effects of rosiglitazone on Aβ1–42 expression in PC-12 cells. (J) ELISA analysis of the effects of insulin on Aβ1–42 expression in PC-12 cells. Mean values ± SEMs are representative of three independent isolations and three independent samples. Significant differences between the treatment groups and the control group were determined via one-way ANOVA and the Dunnett multiple comparison procedure. (*P < 0.05, **P < 0.01, ***P < 0.001 compared with the BPA single treatment group, #P < 0.05, ##P < 0.01).
